Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Rixa Health vs WeightRx

Rixa Health
Graded #320

Lower grade

vs+11.599999999999994
WeightRx
Graded #85

Higher grade

The verdict

WeightRx takes it — 72.1/100 to 60.5/100.

WeightRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. WeightRx is a telehealth provider publishing compounded semaglutide at $250/mo and compounded tirzepatide at $83/mo.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueWeightRx +46
45
91
Dose & formulationWeightRx +13
51
64
Clinical oversightRixa Health +3
85
82
Labs & monitoringRixa Health +10
63
53
FulfillmentRixa Health +13
78
65
Contract termsWeightRx +14
41
55
Rixa Health · left barWeightRx · right bar

The numbers

MetricRixa HealthWeightRx
WeighScore60.5/10072.1/100
GradeCC
Scorecard rank#320#85
SemaglutideNot disclosed$250/mo (compounded)
TirzepatideNot disclosed$83/mo (term not published, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
Rixa Health

Graded #320 · C

Strengths

  • Functional-medicine, root-cause clinical approach
  • Compounded and oral semaglutide plus tirzepatide offered
  • Board-certified DO and FNP providers with years of experience
  • Medication bundled with visits into a single price
  • No charge until after approval

Where it loses points

  • No public monthly pricing; quoted only during consultation
  • Relies on compounded GLP-1, which is not FDA-approved as a finished drug
  • A handful of states still listed as coming soon
  • Branded GLP-1 medications are not the primary offering
  • Requires ongoing monthly follow-up commitment
WeightRx

Graded #85 · C

Strengths

  • The tirzepatide figure is published up front, and it is genuinely low against the field
  • Both molecules are offered
  • No membership charge is advertised alongside the medication rate

Where it loses points

  • The $83 monthly rate is advertised as '$83/month ($997/year)', which is twelve months of it — no month-to-month rate is separately published, and the terms state that a rate is locked for its full term
  • Both product pages linked from the homepage return 404, so the plan terms cannot be read before intake
  • Six- and twelve-month plans are non-refundable, and eligible refunds carry a 5% processing fee
  • No dose strength is published anywhere, so what the $83 buys is not stated
  • The named operator is Twist G Marketing, LLC rather than a clinical entity, and the terms carry a binding arbitration and class-action waiver

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard